gastric cancer

News

FDA grants Priority Review of Astellas’ zolbetuximab BLA

Astellas Pharma Inc has announced that the US Food and Drug Administration (FDA) has accepted and granted Priority Review of its zolbetuximab Biologics License Application

Oncology

ASCO 2023 – Mark Reisenauer

As we approach the last of our exclusive coverage of ASCO 2023, editor-in-chief Jonah Comstock speaks with Mark Reisenauer, president of US commercial at Astellas.

News

Astellas GLOWing as Claudin drug aces gastric cancer trial

Pair of positive phase 3 studies means company will file for approval of zolbetuximab soon.

News

Second phase 3 trial extends Astellas' lead in claudin 18.2 ...

Astellas has confirmed it is out in front among developers of drugs targeting claudin 18.2, after a second phase 3 trial of zolbetuximab hit its objectives.

News

Opdivo backed by NICE for rare gastro-oesophageal cancers

Bristol-Myers Squibb's Opdivo has been recommended as a treatment for around 3,000 people with rare forms of gastro-oesophageal cancer via the NHS in England and Wales.

News

Astellas nabs lead in claudin 18.2 after positive stomach ca...

Astellas Pharma's zolbetuximab – currently leading an expanding pack of drugs targeting claudin 18.2 – has shown efficacy in the first of a pair of phase 3 trials of gastric or gastroesopha

FDA grants Priority Review of Astellas’ zolbetuximab BLA

ASCO 2023 – Mark Reisenauer

Astellas GLOWing as Claudin drug aces gastric cancer trial

Second phase 3 trial extends Astellas' lead in claudin 18.2 ...

Opdivo backed by NICE for rare gastro-oesophageal cancers

Astellas nabs lead in claudin 18.2 after positive stomach ca...

OpenBind unveils its first AI model for drug discovery

Discover a new era of healthcare panel engagement: Grounded ...

gastric cancer

Editor's Picks